ISG20

Across TCGA pan-cancer cohorts, ISG20 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ISG20 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ISG20 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ISG20 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where ISG20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.666	0.207	.001	22	view →
GBM	DFS	Median	All	0.636	0.862	.001	21	view →
LSCC	DFS	Median	II,III,IV	0.533	0.855	.007	12	view →
UCEC	DFS	Quartile	III,IV	1.000	0.238	.008	8	view →
CCRCC	DFS	Median	II,III,IV	0.778	0.439	.005	7	view →
COAD	DFS	Tertile	All	0.883	1.000	.038	6	view →
LUAD	DFS	Quartile	II,III,IV	0.822	0.208	.018	4	view →
HNSC	DFS	Quartile	III,IV	1.000	0.349	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ISG20–PDAC (OS)

Open the PDAC breakdown →